• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Larochelle Karen covered exercise/tax liability with 604 shares, decreasing direct ownership by 21% to 2,225 units (SEC Form 4)

    3/14/24 4:47:33 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PXMD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    LaRochelle Karen

    (Last) (First) (Middle)
    C/O PAXMEDICA, INC.
    303 SOUTH BROADWAY, SUITE 125

    (Street)
    TARRYTOWN NY 10591

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    PaxMedica, Inc. [ PXMD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/12/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/12/2024 F(1) 604 D $0.69 2,225 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units.
    /s/ Stephen D. Sheldon, Jr. Attorney-in-Fact 03/14/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PXMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PXMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PXMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Weisman Howard J. covered exercise/tax liability with 2,927 shares, decreasing direct ownership by 8% to 34,748 units (SEC Form 4)

      4 - PaxMedica, Inc. (0001811623) (Issuer)

      3/14/24 4:50:14 PM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Sheldon Stephen covered exercise/tax liability with 3,356 shares, decreasing direct ownership by 25% to 10,137 units (SEC Form 4)

      4 - PaxMedica, Inc. (0001811623) (Issuer)

      3/14/24 4:49:38 PM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Rome Zachary covered exercise/tax liability with 4,904 shares, decreasing direct ownership by 32% to 10,244 units (SEC Form 4)

      4 - PaxMedica, Inc. (0001811623) (Issuer)

      3/14/24 4:48:37 PM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $PXMD
    SEC Filings

    See more
    • PaxMedica Inc. filed SEC Form 8-K: Leadership Update

      8-K - PaxMedica, Inc. (0001811623) (Filer)

      2/6/25 4:05:19 PM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form NT 10-Q filed by PaxMedica Inc.

      NT 10-Q - PaxMedica, Inc. (0001811623) (Filer)

      11/14/24 4:05:10 PM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by PaxMedica Inc.

      EFFECT - PaxMedica, Inc. (0001811623) (Filer)

      10/16/24 12:15:11 AM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $PXMD
    Financials

    Live finance-specific insights

    See more
    • PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101

      TARRYTOWN, New York, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (NASDAQ:PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, announced today the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (RLS). These assets were previously dedicated to the study of suramin's potential efficacy in treating acute kidney injury resulting from chronic kidney disease. The newly acquired data from RLS will play a crucial role in bolstering PaxMedica's ongoing efforts to support the submission for the approval of PAX-101, specifically for the treatment of African Sleeping Sickness cause

      10/31/23 8:00:00 AM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $PXMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

      SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

      11/14/24 7:22:38 PM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by PaxMedica Inc. (Amendment)

      SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

      2/13/24 8:11:14 PM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by PaxMedica Inc.

      SC 13G - PaxMedica, Inc. (0001811623) (Subject)

      11/29/23 4:33:08 PM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $PXMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions

      BOSTON, MA / ACCESSWIRE / January 14, 2025 / PaxMedica, Inc. (OTC:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce it has received a Notification to Grant Patent Right for Chinese Invention Patent Application No: 2020800553323, Compositions and methods for treating cognitive, social, or behavioral disabilities and neurodevelopmental disorders, such as those found in individuals impacted by autism.Howard Weisman, CEO of PaxMedica commented, "This is an extraordinary milestone for PaxMedica, as this is the first jurisdiction in the world where intellectual property protection of any form of suramin has been a

      1/14/25 8:00:00 AM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • PaxMedica Secures Immediate Exercise of Warrants

      TARRYTOWN, NY / ACCESSWIRE / September 3, 2024 / PaxMedica, Inc. (OTC:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,423,080 shares of common stock of the originally issued in November 2023, having an exercise price of 1.30 per share, at a reduced exercise price of $0.20 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-275416). The offering is expected to close on or about

      9/3/24 8:00:00 AM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection

      Company provides update on regulatory progress towards US NDA submission TARRYTOWN, NY / ACCESSWIRE / August 27, 2024 / PaxMedica, Inc. (OTC:PINKPXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce a significant milestone in its global health efforts. The Malawi Ministry of Health has informed the company that a patient suffering from the potentially fatal parasitic infection known as Human Africa Trypanosomiasis Brucei Rhodesiense, (HAT), commonly referred to as African Sleeping Sickness, has recently received treatment with PAX-101, an intravenous form of Suramin, and is recovering at home. The Rhodesiense st

      8/27/24 8:00:00 AM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $PXMD
    Leadership Updates

    Live Leadership Updates

    See more
    • PaxMedica Appoints David Hough M.D. as Chief Medical Officer

      Announces Additional Management Changes; Independent Directors Now Majority of Board TARRYTOWN, NY, Aug. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (NASDAQ:PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced the return of David Hough, M.D., as Chief Medical Officer (CMO) of PaxMedica, effective immediately.  Dr. Hough  has been a key consultant to the company during 2023 and was the company's CMO from 2020-2022. He is board-certified in both adult and geriatric psy

      8/16/23 8:30:00 AM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • PaxMedica, Inc. Provides Business Update and Reports Third Quarter 2022 Financial Results

      -PXMD Strengthened Executive Team and Board of Directors With Recent Appointments After IPO in August 2022- -Phase 3 Results for HAT-301 Trial Expected in First Half 2023- TARRYTOWN, NY, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (NASDAQ:PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies ("APT") for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the third quarter of 2022, ended September 30, 2022. Howard Weisman, Chief Executive Officer of PaxMedica, commented, "The third quarter was PaxMedica's first as a publ

      11/15/22 8:00:00 AM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • PaxMedica Appoints Stefan Schwabe MD, PhD as Chief Medical Officer

      Dr. Schwabe brings 30+ years of Clinical Experience in the Pharmaceutical Industry  TARRYTOWN, NY, Oct. 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (NASDAQ:PXMD), a clinical-stage biopharmaceutical company focused on the development of anti-purinergic drug therapies ("APT") for the treatment of disorders with intractable neurologic symptoms such as autism spectrum disorder ("ASD"), today announced the appointment of Dr. Stefan Schwabe MD, PhD as Chief Medical Officer.  In this role, Dr. Schwabe will be responsible for overseeing and directing product development activities including pre-clinical, clinical, regulatory and pharmaceutical sciences for PaxMedica's pipeli

      10/24/22 8:00:00 AM ET
      $PXMD
      Medicinal Chemicals and Botanical Products
      Health Care